# Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)

> **NCT03080805** · PHASE3 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 240 (estimated)

## Conditions studied

- HER2 Positive Metastatic Breast Cancer

## Interventions

- **DRUG:** Pyrotinib Plus Capecitabine
- **DRUG:** Lapatinib Plus Capecitabine

## Key facts

- **NCT ID:** NCT03080805
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-05-03
- **Primary completion:** 2019-03-31
- **Final completion:** 2021-03
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2020-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03080805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03080805, "Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03080805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*